뇌질환의 혁신, 뉴로벤티(NeuroVenti)

ABOUT

NeuroVenti contributes to creating a society where we work together.

NeuroVenti will grow into a world-class leader in therapeutics for intractable brain diseases.

NeuroVenti is committed to developing a world-leading therapeutic for autism spectrum disorder(ASD).

Despite advances in medicine, neurodevelopmental disorders — including autism spectrum disorder (ASD) — still lack adequate pharmacological treatments, leaving many individuals and their families to bear a heavy burden. Drawing on more than two decades of research in developmental disorders, NeuroVenti is working to develop the first therapeutics for the core symptoms of autism by discovering innovative drug candidates. The pathophysiology of neurodevelopmental disorders arises from the combined action of multiple neurotransmitters, neuromodulators, and hormones; from genetic and environmental risk factors; and from the interplay among interconnected brain regions. Because of this complexity, the long-held assumption that modulating a single target would suffice has proven inadequate. NeuroVenti's proprietary target-control technology enables the precise regulation of higher-order brain function — with applications across intractable brain diseases such as treatment-resistant depression, and developmental disorders including ASD, ADHD, and Tourette's syndrome. With clinical success as our highest priority, NeuroVenti develops science-based therapeutics that integrate the latest knowledge and techniques across medicine, pharmacology, and molecular biology. We will continue to grow into a world-class leader in intractable brain disorders through innovative treatments, and we welcome your continued interest in and support of our work toward a society of brain well-being.
CEO Chan Young Shin